Feb. 13, 2022
MRTX1719
PRMT5 inhibitor preclinical (MTAP-deleted cancers) from fragment-based design + SBDD J. Med. Chem. Mirati Therapeutics
PRMT5 inhibitor preclinical (MTAP-deleted cancers) from fragment-based design + SBDD J. Med. Chem. Mirati Therapeutics